Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
Poseida Therapeutics (PSTX) reported strong Q3 2024 results, generating $71.7 million in revenue and achieving $20.2 million in net income. The company has been cash flow positive for the first nine months of 2024, securing $130 million in milestone and upfront payments. Their lead candidate P-BCMA-ALLO1 showed a 91% overall response rate in Phase 1 trials for multiple myeloma. The company expanded collaborations with Roche and Astellas, with cash runway extended into early 2026. Their cash position stands at $230.9 million as of September 30, 2024.
Poseida Therapeutics (PSTX) ha riportato risultati solidi per il terzo trimestre del 2024, generando 71,7 milioni di dollari di ricavi e raggiungendo 20,2 milioni di dollari di utile netto. L'azienda ha registrato flussi di cassa positivi per i primi nove mesi del 2024, assicurandosi 130 milioni di dollari in pagamenti per traguardi e anticipati. Il loro candidato principale P-BCMA-ALLO1 ha mostrato un 91% di tasso di risposta complessivo negli studi di Fase 1 per il mieloma multiplo. L'azienda ha ampliato le collaborazioni con Roche e Astellas, con la disponibilità di cassa estesa fino all'inizio del 2026. La loro posizione di cassa ammonta a 230,9 milioni di dollari al 30 settembre 2024.
Poseida Therapeutics (PSTX) reportó resultados sólidos en el tercer trimestre de 2024, generando 71,7 millones de dólares en ingresos y logrando 20,2 millones de dólares en ingresos netos. La empresa ha tenido flujo de caja positivo durante los primeros nueve meses de 2024, asegurando 130 millones de dólares en pagos por hitos y anticipados. Su candidato principal P-BCMA-ALLO1 mostró una tasa de respuesta global del 91% en ensayos de Fase 1 para el mieloma múltiple. La empresa amplió colaboraciones con Roche y Astellas, con un capital disponible extendido hasta principios de 2026. Su posición de efectivo se sitúa en 230,9 millones de dólares al 30 de septiembre de 2024.
포세이다 테라퓨틱스 (PSTX)는 2024년 3분기 강력한 실적을 보고하며 7,170만 달러의 수익을 올리고 2,020만 달러의 순이익을 달성했습니다. 이 회사는 2024년 첫 9개월 동안 긍정적인 현금 흐름을 기록했으며, 1억 3천만 달러의 이정표 및 선불 지급을 확보했습니다. 그들의 주요 후보인 P-BCMA-ALLO1은 다발성 골수종의 1상 시험에서 91%의 전체 반응률을 보였습니다. 회사는 로슈 및 아스텔라스와의 협력을 확대하고, 현금 런웨이가 2026년 초까지 연장되었습니다. 2024년 9월 30일 기준으로 그들의 현금 자산은 2억 3천9백만 달러입니다.
Poseida Therapeutics (PSTX) a annoncé de solides résultats pour le troisième trimestre de 2024, générant 71,7 millions de dollars de revenus et atteignant 20,2 millions de dollars de bénéfice net. L'entreprise a enregistré un flux de trésorerie positif au cours des neuf premiers mois de 2024, sécurisant 130 millions de dollars en paiements d'étape et anticipés. Leur candidat principal P-BCMA-ALLO1 a montré un taux de réponse global de 91% lors des essais de Phase 1 pour le myélome multiple. L'entreprise a élargi ses collaborations avec Roche et Astellas, avec une visibilité de trésorerie prolongée jusqu'au début 2026. Sa position de trésorerie s'élève à 230,9 millions de dollars au 30 septembre 2024.
Poseida Therapeutics (PSTX) meldete starke Ergebnisse im dritten Quartal 2024 mit einem Umsatz von 71,7 Millionen Dollar und einem Nettoeinkommen von 20,2 Millionen Dollar. Das Unternehmen hat in den ersten neun Monaten 2024 einen positiven Cashflow erzielt und sich 130 Millionen Dollar an Meilenstein- und Vorauszahlungen gesichert. Ihr Hauptkandidat P-BCMA-ALLO1 zeigte eine 91% Gesamtansprechrate in Phase-1-Studien für multiples Myelom. Das Unternehmen hat die Zusammenarbeit mit Roche und Astellas ausgeweitet, und die finanzielle Laufzeit wurde bis Anfang 2026 verlängert. Ihre Bargeldposition beträgt zum 30. September 2024 230,9 Millionen Dollar.
- Generated $71.7 million in Q3 2024 revenue, up from $9.4 million in Q3 2023
- Achieved $20.2 million net income in Q3 2024, compared to $31.8 million loss in Q3 2023
- Secured $130 million in milestone and upfront payments year-to-date
- P-BCMA-ALLO1 showed 91% overall response rate in Phase 1 trials
- Cash position of $230.9 million with runway into early 2026
- Research and development expenses increased to $41.9 million in Q3 2024 from $37.5 million in Q3 2023
- General and administrative expenses rose to $10.1 million from $8.1 million year-over-year
- Net loss of $35.4 million for the nine months ended September 30, 2024
Insights
The Q3 2024 results demonstrate significant financial improvement and strategic progress. Key highlights include:
- Revenue Growth: Q3 revenue surged to
$71.7M from$9.4M year-over-year, driven by milestone payments and R&D reimbursements - Cash Position: Strong balance sheet with
$230.9M in cash and equivalents - Partnership Success: Generated
$130M in milestone/upfront payments, with$49M in R&D reimbursements - Cash Flow: Achieved positive cash flow for first 9 months of 2024
The extended cash runway into early 2026 and potential for additional milestone payments from partnerships provide financial stability. The company's transition from cash-burning to cash-flow positive marks a significant milestone for a clinical-stage biotech.
The clinical progress is particularly noteworthy with P-BCMA-ALLO1 showing impressive results:
- High Efficacy:
91% overall response rate in the optimized lymphodepletion arm - Strong Safety Profile: No dose-limiting toxicities and low rates of adverse events
- Fast Response: Median time to response of just 16 days
- RMAT Designation: FDA recognition highlights potential accelerated pathway to market
The expansion into autoimmune diseases with P-BCMACD19-ALLO1 and the dual-targeting approach could open significant market opportunities. The non-viral manufacturing platform continues to demonstrate advantages in safety and scalability.
Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target
Cash flow positive for the first nine months of 2024;
Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with
Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies
On track to deliver further updates across allogeneic CAR-T pipeline before year-end 2024, including presentations at the 66th American Society of Hematology Annual Meeting in December
"Poseida continues to make excellent progress across all of our key initiatives, highlighted by compelling data presentations from our pipeline of innovative, non-viral allogeneic cell therapy and genetic medicine programs, the expansion and advancement of our collaborations with Roche and Astellas, and our science-backed strategy to apply our platform to the large and growing opportunity for CAR-T in autoimmune diseases," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida Therapeutics. "As a result, we have generated
Recent Accomplishments
Cell Therapy
Expanded strategic global collaboration with Roche, including ongoing pipeline progress and the nomination of a new dual CAR-T development candidate.
- The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in hematologic malignancies, including multiple myeloma. Poseida and Roche now have three programs under their collaboration, including P-BCMA-ALLO1, an allogeneic CAR-T therapy in Phase 1/1b development for multiple myeloma, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T candidate in Phase 1 development for B-cell malignancies. Roche has the option to nominate additional development candidates in the future.
- P-BCMA-ALLO1 continues to be positioned as a leading clinical-stage allogeneic CAR-T therapy with a compelling and differentiated profile: interim Phase 1 data presented at the International Myeloma Society (IMS) annual meeting in September showed a
91% overall response rate (ORR) in an optimized lymphodepletion arm, including a100% ORR in B-cell maturation antigen (BCMA)-naïve patients, and an86% ORR in those who had received at least one prior BCMA- and/or G protein-coupled receptor class C group 5 member D (GPRC5D)-targeting treatment modality, along with differentiated safety results with no dose-limiting toxicities, low rates of cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS) all Grade 2 or less and no graft vs. host disease or Parkinsonism. No anti-myeloma bridging therapy or prophylaxis with steroids or tocilizumab, no invasive apheresis or manufacturing wait with average time from treatment decision to clinical response of only 3.5 weeks1 (median time to response of 16 days post initial P-BCMA-ALLO1 therapy). The patients in this study had more advanced disease than the myeloma patients studied in clinical trials of approved autologous CAR-T therapies2, and in the intent-to-treat population,100% of patients were infused with P-BCMA-ALLO1. - Poseida's conference call to discuss IMS data featured a fireside chat with leading myeloma experts that highlighted key aspects of the data and provided context on current treatment approaches. The experts highlighted that off-the-shelf availability allows patients to start therapy fast, without need for bridging therapy commonly required by autologous CAR-T, and in some cases, offers a solution for patients who are ineligible for autologous treatments; rapid clinical responses; attractive safety profile; ability to treat patients on an outpatient basis; and ability to treat BCMA-exposed patients as key benefits observed in the trial.
- P-BCMA-ALLO1 development continues, with ongoing patient enrollment in the recently initiated Phase 1/1b trial that is using the same lymphodepletion regimen as the optimized lymphodepletion arm described above, including two different cell doses. During the third quarter, P-BCMA-ALLO1 was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the
U.S. Food and Drug Administration (FDA) to treat relapsed/refractory multiple myeloma after three or more prior lines of therapies including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. - Poseida has secured
from Roche collaboration milestones to-date in 2024, including a milestone payment received in the third quarter related to the initiation of the P-BCMA-ALLO1 Phase 1b clinical trial, and an additional payment for the nomination of the new development candidate in October.$80 million
Progressed the strategic research collaboration and license agreement with Astellas' wholly owned subsidiary Xyphos Biosciences with the formal nomination of the second high potential program target. Both program targets nominated under the collaboration are well-known and validated solid tumor targets.
Accelerating highly differentiated dual targeting allogeneic CAR-T for autoimmune disease with P-BCMACD19-ALLO1 as first pipeline candidate to address this significant market opportunity. P-BCMACD19-ALLO1 is an allogeneic dual CAR-T candidate currently in IND-enabling studies. We believe targeting BCMA and CD19 could provide the potential to enable more complete immune cell depletion than CAR-Ts targeting only one of the antigens, and that targeting BCMA specifically could provide the potential to deplete autoantibodies from plasma cells, which are believed to be a key driver in many autoimmune diseases and not addressed by targeting CD19 alone. Emerging data from an autologous dual CAR-T targeting BCMA and CD19 has thus far substantiated this dual targeting approach. P-BCMACD19-ALLO1 is also positioned to provide the access benefits of an allogeneic product and a potentially attractive safety profile derived from Poseida's non-viral TSCM approach and other features unique to the Company's CAR-T platform, such as its proprietary safety switch.
__________________________________ |
1 Based on interim data from Phase 1 P-BCMA-ALLO1 clinical trial announced in September 2024, Arms A and B. |
2 No head-to-head trial has been conducted evaluating P-BCMA-ALLO1 against other products included herein. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, study design, and other factors. |
Strengthened Poseida's innovation profile and emerging leadership in allogeneic CAR-T with new data at the Society of Hematologic Oncology (SOHO) Twelfth Annual Meeting in September and the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting & Pre-Conference Programs in November.
- A new case study demonstrating the reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in a patient with relapsed multiple myeloma was presented at SOHO. The patient attained and remains in stringent complete response over 10 months after CAR-T reactivation. This case highlights the potential of Poseida's TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence. The Company believes this is the first time that a T-cell engager has been seen to reactivate a CAR-T therapy.
- New preclinical data highlighting the potential of Poseida's platform to design and manufacture CAR-TCR-T cells that are rich in stem cell memory T cell (TSCM) and central memory T cells (TCM) for potential use in solid tumors will be presented at SITC on November 9. In solid tumors, multi-antigens are believed to be necessary for efficacy, and CAR+TCR-T cells can recognize and kill single and double antigen target cells and show the potential to synergize with T-cell engagers. Key highlights from the SITC presentation include:
- CAR+TCR-T cells were shown to control single and double antigen-positive tumor growth in vivo, with sustained persistence.
- T-cell engager was used to re-activate and re-direct engrafted CAR+TCR-T cells to control a secondary tumor challenge expressing different antigens echoing the patient case study presented at SOHO and suggesting an approach to address heterogeneous tumors and/or tumors whose composition evolves over time.
Continued to enroll patients in the Phase 1 clinical trial of P-CD19CD20-ALLO1. In light of the competitive environment for therapies targeting CD19 and CD20, Poseida and Roche anticipate providing initial clinical data from the trial in 2025 once a more complete dataset of the program is available.
Genetic Medicines
Demonstrated ongoing leadership in development of non-viral approaches to genetic medicines, supported by data presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Scientific Meeting featuring P-KLKB1-101, a non-viral, liver-directed genetic medicine that uses the Company's Cas-CLOVER™ Site-Specific Gene Editing System. The data showed high-fidelity gene editing at KLKB1 for the targeted correction of hereditary angioedema (HAE), the ability for controlled dose response, favorable tolerability and liver editing approaching the desired therapeutic range. The data reinforce the potential of Cas-CLOVER to be a unique and attractive gene editing tool for a variety of diseases, starting with HAE and KLKB1 editing.
In addition, Poseida had a successful INTERACT meeting with the
Other Operational Updates and Upcoming Events
Manufacturing Updates
The Company continues to advance its platform process and analytical capabilities for allogeneic cell therapy manufacturing. Recent analytical enhancements have enabled more precise evaluation of prospective donors as well as providing improved characterization of drug product attributes.
Cell Therapy R&D Day
Poseida will host a cell therapy-focused R&D Day on November 14, 2024, to highlight progress and further opportunities across its clinical-stage and earlier-stage pipeline of differentiated allogeneic CAR-T therapies in oncology and autoimmune disease.
The virtual event and access to the live webcast will be available through the following registration link: https://wsw.com/webcast/cc/pstx7/1467684. Registration for this virtual event and access to a replay of the live webcast will also be available on the Investors & Media section of www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.
Financial Results for the Third Quarter 2024
Revenues
Revenues were
Research and Development Expenses
Research and development expenses were
Research and development expenses were
General and Administrative Expenses
General and administrative expenses were
Net Income (Loss)
Net income was
Cash Position
As of September 30, 2024, the Company's cash, cash equivalents and short-term investments balance was
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral transposon-based DNA delivery system, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, expected plans with respect to clinical trials, including timing of regulatory meetings and submissions and approvals and clinical data updates; potential fees, reimbursements, milestones, royalty payments and other payments that the Company may receive pursuant to its collaboration agreements with Roche and Astellas, including related timing; anticipated timelines and milestones with respect to the Company's development programs and manufacturing activities and capabilities; the potential capabilities, benefits and opportunities of the Company's technology platforms and product candidates, including the efficacy, safety and tolerability profile of such product candidates or any ability to deliver therapeutic approaches in autoimmune disease; the quote from Dr. Yarema; estimates of the Company's cash balance, cash runway, expenses, capital requirements and any future revenue; the Company's ability to exploit and consummate additional business development opportunities, including with Roche and Astellas, and any anticipated upside potential and impact on the Company's cash balance and cash runway; the Company's ability to attract and/or retain new and existing collaborators with relevant expertise and its expectations regarding the potential benefits to be derived from any such collaborations; and the Company's plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the Company's reliance on third parties for various aspects of its business; risks associated with conducting clinical trials; whether any of the Company's product candidates will be shown to be safe and effective; the Company's ability to finance continued operations; competition in the Company's target markets; the Company's ability to protect its intellectual property; risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry; the Company's ability to retain key scientific or management personnel; the fact that the Company will have limited control over the efforts and resources that its collaborators devote to advancing development programs under their respective collaboration agreements; the fact that the Company may not receive the potential fees, reimbursements and payments under the collaboration agreements; the ability of the Company's collaborators to early terminate the collaborations, such that the Company may not fully realize the benefits of the collaborations; and the other risks described in the Company's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Poseida Therapeutics, Inc. | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Revenues: | ||||||||||||||||
Collaboration revenue | $ | 71,748 | $ | 9,352 | $ | 125,863 | $ | 39,708 | ||||||||
Total revenue | 71,748 | 9,352 | 125,863 | 39,708 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 41,914 | 37,482 | 130,382 | 114,727 | ||||||||||||
General and administrative | 10,092 | 8,092 | 32,072 | 28,576 | ||||||||||||
Total operating expenses | 52,006 | 45,574 | 162,454 | 143,303 | ||||||||||||
Income (loss) from operations | 19,742 | (36,222) | (36,591) | (103,595) | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest expense | (2,295) | (2,236) | (6,807) | (6,404) | ||||||||||||
Other income, net | 2,831 | 6,787 | 8,031 | 12,025 | ||||||||||||
Net income (loss) before income tax | 20,278 | (31,671) | (35,367) | (97,974) | ||||||||||||
Income tax expense | (43) | (107) | (43) | (107) | ||||||||||||
Net income (loss) | $ | 20,235 | $ | (31,778) | $ | (35,410) | $ | (98,081) | ||||||||
Net income (loss) per share, basic and diluted | $ | 0.21 | $ | (0.35) | $ | (0.37) | $ | (1.11) | ||||||||
Weighted-average number of shares outstanding, | 97,160,467 | 91,898,347 | 96,716,649 | 88,321,943 | ||||||||||||
Weighted-average number of shares outstanding, | 98,219,947 | 91,898,347 | 96,716,649 | 88,321,943 |
SELECTED BALANCE SHEET DATA | ||||||||
September 30, | December 31, | |||||||
2024 | 2023 | |||||||
(Unaudited) | ||||||||
Cash, cash equivalents and short-term investments | $ | 230,852 | $ | 212,202 | ||||
Total assets | 293,577 | 273,885 | ||||||
Total liabilities | 206,366 | 170,184 | ||||||
Total stockholders' equity | 87,211 | 103,701 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-third-quarter-of-2024-302299335.html
SOURCE Poseida Therapeutics, Inc.
FAQ
What was Poseida Therapeutics (PSTX) revenue in Q3 2024?
What was the response rate for PSTX's P-BCMA-ALLO1 in Phase 1 trials?
How much cash does PSTX have as of Q3 2024?